Manhattan Pharmaceuticals is a specialty pharmaceutical development company based in New York City. Manhattan is focused on the licensing and development of specialty pharmaceuticals for major therapeutic areas with medical need, such as obesity. The company s lead compound, oleoyl-estrone, is an orally administered compound for the treatment of obesity that has been shown to cause significant weight loss in preclinical studies. The company is also developing a proprietary lingual spray formulation of Propofol, one of the world's best-selling general anesthetics, as a sedative-hypnotic prior to diagnostic and therapeutic procedures. The company has partnerships with Indevus Pharmaceuticals for the development of CT-3 for the treatment of pain, and with Bausch & Lomb for Manhattan's Avantix cataract removal device. Established in 2001, Manhattan Pharmaceuticals merged with Atlantic Technology Ventures in 2003.